Podcasts about Sunovion

In this CME podcast, Dr. Andrew Cutler and Dr. Roger McIntyre discuss the use of potentially unsafe drug combinations in patients with treatment-resistant psychiatric conditions. They review situations where complex medication regimens may be necessary and how clinicians may proceed in these instances. By addressing these topics, the podcast offers guidance on balancing the potential benefits of combination therapies with the risks associated with polypharmacy in psychiatric care.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Identify common potentially unsafe drug combinations that may be considered in treatment-resistant cases Evaluate the risks and benefits of prescribing potentially unsafe drug combinations for treatment-resistant patients, considering factors such as efficacy, adverse effects, and patient-specific characteristics Develop strategies to monitor and manage patients prescribed potentially unsafe drug combinations Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour. Released: March 26, 2025*   Expiration: March 25, 2028 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-01 Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until March 25, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, and cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education take responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, ON, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, NEI and HMP planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, and Steven S. Simring, MD, MPH. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

In this CME episode, Drs. Andrew Cutler and Roger McIntyre discuss the challenges and importance of diagnosing bipolar disorder as early as possible in the course of the illness. They also review strategies to achieve a correct diagnosis to provide the most efficacious and tolerable treatments available for bipolar disorder. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Employ effective screening tools and assessment strategies to enhance diagnostic accuracy and achieve early diagnosis of bipolar disorder Develop patient-centered treatment plans that incorporate current evidence and individual patient factors Utilize shared decision-making approaches to optimize treatment outcomes for patients with bipolar disorder Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 01, 2024*   Expiration: October 31, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-BD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 31, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, Ontario, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Alkermes, Inc.

In this CME episode, Dr. Andy Cutler interviews Dr. Leslie Citrome about the impact of tardive dyskinesia on patient-reported outcomes and quality of life. They discuss how to correctly assess and diagnose tardive dyskinesia, as well as effective management strategies that incorporate the individual needs of patients.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Understand the physical, psychological, social, and occupational impacts of tardive dyskinesia (TD) on patients Identify clinical tools and patient-reported outcome measures to assess the severity and impact of TD Formulate evidence-based treatment strategies for TD that enhance patient outcomes and quality of life Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: October 23, 2024*   Expiration: October 22, 2027 *NEI maintains a record of participation for six (6) years.   CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-TD   Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 22, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer, Reviva (options) The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.

In this CME episode, Dr. Andrew Cutler interviews Dr. Dani Cabral about current and novel diagnostic tools and treatments for Alzheimer's disease. Optional CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the potential role of multimodal imaging and biomarker strategies in the diagnostic process for Alzheimer's disease Assess the safety and efficacy of novel disease-modifying pharmacological treatments for Alzheimer's disease Describe potential future advancements in the diagnosis and treatment of Alzheimer's disease Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Dani Cabral, MD Assistant Clinical Professor, Departments of Neurology and of Psychiatry, University of Arizona College of Medicine, Phoenix, AZ Dementia Specialist, Banner Sun Health Research Institute, Sun City, AZ Consultant/Advisor: Eisai, Lilly, Roche/Genentech Interview Questions Author Caroline L. O'Brien, MS Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewers have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Eisai. Released: December 27, 2023      CE credit expires: December 27, 2026

In this CME episode, Dr. Andrew Cutler interviews Dr. Jeffrey Strawn about the role of pharmacogenomic testing in guiding treatment of major depressive disorder (MDD). They discuss how pharmacogenomic testing works, the impact of failed treatments and side effects on patients with MDD, and the clinical applications and future directions of pharmacogenomic testing. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-GEN Learning Objectives: After completing this educational activity, you should be better able to: Recognize the role of a patient's genetics in informing the efficacy and tolerability of antidepressants Consider opportunities to use pharmacogenomics as an evidence-based tool that can be employed to inform clinical decision making Implement pharmacogenomic testing to optimize patient outcomes, including symptom improvement, medication response, and remission rate Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Jeffrey R. Strawn, MD Professor, Department of Psychiatry and Behavioral Neuroscience and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH Grant/Research: Allergan/AbbVie Consultant/Advisor: Cerevel, Intra-Cellular, Otsuka Pre-Interview Author Gabriela Alarcón, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Myriad Genetics. Released: December 13, 2023      CME/CE credit expires: December 13, 2026

In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about the impact of residual symptoms on patients with major depressive disorder, as well as treatment modifications to address residual symptoms in these individuals. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the burden of residual symptoms in patients with major depressive disorder (MDD) Implement measurement-based care to assess residual MDD symptoms Modify treatment strategies to address residual MDD symptoms, including cognitive impairment, anhedonia, emotional blunting, and sexual dysfunction Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Vladimir Maletic, MD, MS Clinical Professor, Department of Psychiatry and Behavioral Science, University of South Carolina School of Medicine Greenville, SC Consultant/ Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Biogen/Sage, Boehringer Ingelheim, Cervel, Intra-Cellular, Janssen, Jazz, Lundbeck, Neurelis, Neumora, Noven, Otsuka, Pax Medica, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Axsome, Corium, Intracellular, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda Pre-Interview Author Caroline L. O'Brien, MS Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Takeda. Released: November 29, 2023      CME/CE credit expires: November 29, 2026

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/whos-at-risk-for-tardive-dyskinesia-9044 Featuring faculty Gregory Mattingly, MD, moderated by Gregg Sherman, MD. SummaryTardive Dyskinesia (TD) exerts a profound negative impact across a patient's life, including physical and cognitive domains and psychosocial functioning. This affects quality of life (QoL), increases hospitalizations and is associated with speech and eating difficulties, decreased employment, social withdrawal, stigmatization, and amplified emotional distress. In this podcast, hear from a patient who suffered with TD for years before diagnose, and discuss how to identify and support patients with TD.Learning ObjectivesUpon completion of this activity, learners should be able to:Identify the early manifestations of tardive dyskinesia (TD) in patients on antipsychotic therapyRecognize the burden associated with untreated TD and the consequences of delayed diagnosisThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).Summary of Individual DisclosuresAngela Golden has disclosed the following financial relationships:Consultant: SetPoint (obesity), WW (obesity)Advisor: Currax (obesity), Genesis (obesity), Lilly (obesity), Novo Nordisk (obesity), Acela (hypothyroidism)Speaker: Currax (obesity), Novo Nordisk (obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Greg Mattingly has disclosed the following financial relationship:Consultant: AbbVie, Alkermes, Axsome, Biogen, Corium, Eisai, Ironshore, Intra-Cellular, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Redax, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, TevaSpeaker: AbbVie, Alkermes, Axsome, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris PharmaContracted Research: AbbVie, Alkermes, Akili, Axsome, Boehringer Ingelheim, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, Neurocrine Biosciences, NLS Pharmaceuticals, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, TevaAll his disclosures are related to mental healthFaculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial Support This activity is supported by an independent medical education grant from Neurocrine Biosciences, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/managing-tardive-dyskinesia-9045Featuring faculty Gregory Mattingly, MD, moderated by Gregg Sherman, MD.SummaryBesides identification of patients with Tardive Dyskinesia (TD), management options have not always provided much, if any, relief. Traditional approaches to managing TD were not only questionable, and some were potentially harmful, but the availability of newer medications has ushered in a new era in TD management. In this activity, discuss management principles and review two cases to put TD management into practice.This podcast was recorded and is being used with permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Individualize the management of TD using evidence-based strategies that target uncontrolled movementsThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Summary of Individual DisclosuresAngela Golden has disclosed the following financial relationships:Consultant: SetPoint (obesity), WW (obesity)Advisor: Currax (obesity), Genesis (obesity), Lilly (obesity), Novo Nordisk (obesity), Acela (hypothyroidism)Speaker: Currax (obesity), Novo Nordisk (obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Greg Mattingly has disclosed the following financial relationship:Consultant: AbbVie, Alkermes, Axsome, Biogen, Corium, Eisai, Ironshore, Intra-Cellular, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Redax, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, TevaSpeaker: AbbVie, Alkermes, Axsome, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris PharmaContracted Research: AbbVie, Alkermes, Akili, Axsome, Boehringer Ingelheim, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, Neurocrine Biosciences, NLS Pharmaceuticals, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, TevaAll his disclosures are related to mental healthFaculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial Support This activity is supported by an independent medical education grant from Neurocrine Biosciences, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

In this CME episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Sarah Vinson about the ethicality and morality of involuntary treatment for serious mental illness (SMI), the relationship between SMI and the criminal justice system, and community-based changes that are being pursued to improve treatment and reduce the criminalization of SMI. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-SMI Learning Objectives: After completing this educational activity, you should be better able to: Recognize the neuroethics involved in involuntary treatment of serious mental illness Identify methods to prevent patients with serious mental illness from entering the criminal justice system, including the utility of diversion programs Institute community-based changes that have the potential to reduce the criminalization of serious mental illness, both on the individual and the policy level Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity does not pertain to pharmacology and is worth 0.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Interprofessional Continuing Education: IPCE credit for learning and change Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewees Stephen M. Stahl, MD, PhD, DSc (Hon.) Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK Editor-in-Chief, CNS Spectrums Director of Psychopharmacology Services, California Department of State Hospitals Grant/Research: Acadia, Alkermes, Allergan/AbbVie, Arbor, AssureX, AstraZeneca, Avanir, Axovant, Biogen, Boehringer Ingelheim Braeburn, BristolMyer Squibb, Celgene, CeNeRex, Cephalon, Daiichi Sankyo-Brazil, Dey, Eisai, Forest, Genomind, Glaxo Smith Kline, Harmony Biosciences, Indivior, Intra-Cellular, Ironshore, Janssen, JayMac, Jazz, Lilly, Lundbeck, Merck, Neurocrine, Neuronetics, Novartis, Otsuka, Pear, Pfizer, Reviva, Roche, Sage, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Teva, Tonix, Torrent, Vanda Consultant/Advisor: Acadia, Adamas, Alkermes, Allergan/AbbVie, Altus, Arbor, AstraZeneca, Avanir, Axovant, Axsome, Biogen, Biomarin, Biopharma, Celgene, Cerevel, ClearView, Clexio, Concert, DepotMed, Done, EMD Serono, Eisai, Enveric, Eurolink, Fabre-Kramer, Ferring, Forest, Gedeon Richter, Genetica, Genomind, Innovative Science Solutions, Impel, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Libbs, Lilly, Lipidio, Longboard, Lundbeck, Merck, Neos, NeuraWell, Neurocrine, NeuroPharma, Novartis, Noveida, Otsuka, Perrigo, Pfizer, Pierre Fabre, Proxymm, Recordati, Relmada, Reviva, Sage, Saniona, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Taliaz, Teva, Tonix, Tris, Trius, Vanda, Vertex, Viforpharma Speakers Bureau: Acadia, Allergan/AbbVie, Genentech, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Servier, Sunovion, Takeda, Teva Options Holdings: Delix, Genomind, Lipidio, NeuraWell Sarah Y. Vinson, MD, FAPA Interim Department Chair; Clinical Associate Professor; Director, Child and Adolescent Psychiatry Fellowship Program; Department of Psychiatry and Behavioral Sciences, Morehouse School of Medicine, Atlanta, GA Medical Director, Substance Abuse and Mental Health Services Administration (SAMHSA) African American Behavioral Health Center of Excellence, Atlanta, GA No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Alkermes. Released: July 25, 2023      CME/CE credit expires: July 24, 2026

Learn more about Sara Ross and her keynotes: https://premierespeakers.com/sara_ross Chief Vitality Officer at BrainAMPED, a research and strategy firm dedicated to redefining how we succeed at work and thrive in life by sharing brain-based, vitality-enhancing strategies to create healthier, happier, high performing leaders and workplaces. Sara is a contributor at Thrive Global and her work is earning her a reputation as a fresh and thought-provoking voice in the discussions of leadership, work-life balance, emotional intelligence and organizational health. Before founding her company, Sara spent a decade with the Institute for Health and Human Potential, formerly serving as their Vice President and Global Head of Leadership Innovation. As head of faculty, Sara led the delivery of leadership programs, assessments and award-winning coaching and accreditation programs aimed at helping leaders grow their emotional intelligence and be their best, even in the most complex and pressure-filled moments. Sara has worked with Fortune 500 companies such as; UnitedHealth Group, Verizon, Rogers and Allstate; tech companies such as Adobe, WAVE and ATS; financial firms such as Scotiabank, Fidelity, BMO and PwC; pharmaceutical companies such as Sunovion; educational institutes such as Smith College and the University of Toronto, and the leadership team of the NBA's Orlando Magic. Her clients have ranged from surgeons, bankers, lawyers, air traffic controllers and engineers to government agencies, nurses, nonprofits, start-ups and entrepreneurs. This broad perspective and diverse experience help explain why she is often called on to work with some of the most senior, technically sophisticated and skeptical audiences.

What are some differences between biostatisticians in hospitals and the pharma industry? What are some specific skill sets required for these jobs? And how can Bayesian framework be used in benefit-risk assessment of new medical products or interventions? Carl DiCasoli will answer all these questions for you. Carl obtained his PhD in statistics from North Carolina State University and currently is working as the director of biostatistics at Sunovion Pharmaceuticals, where he acts as senior reviewer and lead biostatistician in clinical trials in neurology, designs innovative Bayesian adaptive phase 1 first-in-human single ascending dose study for a new compound at Sunovion and collaborates with Frontier Business Division within Sunovion to drive clinical trials for a digital therapeutics medical device to treat social anxiety. Wait, what is that? I've also seen Carl's name on the Piano World piano forums? And there are words on the street that instead of a statistician, he was almost a professional classical pianist? Let's hear more about it in this episode. Check out this video for Dr. DiCasoli's great piano performance in 2019 San Diego International Amateur Piano Competition Finalist! Please visit our website https://biostatisticspodcast.github.io/ for the latest updates and transcripts of the published episodes. If you have any comments, feedback or suggestions, feel free to email us via biostatisticspodcast@gmail.com or DM us on Twitter @BiostatsPodcast Stay tuned :D Intro Music: Chris - C418 Outro Music: Wet Hands - C418 Powered by Firstory Hosting

Dr. Gerald Maguire is the world's frontrunner in pharmacological treatment research for stuttering. His personal connection with stuttering, academic background, professional experience and international links with top scientists have positioned him as the leading expert on medication's future role in the treatment of stuttering. Dr. Maguire is a professor and Founding Chair of Psychiatry for the American University of Health Sciences School of Medicine in California. He is the principal investigator for CenExel CIT, Global Medical Director for iStutter, and Chair of Research and Development for the World Stuttering Network.Dr. Maguire's disclosures include:Research Grants related to stuttering: Noema, Emalex. Other CNS research grants: Bioexcel, Neurocrine, Jazz, Sunovion, Karuna, Cerevel, Intracellular, Otsuka, AxsomeConsultant/Advisor: Karuna, Sage/Biogen, Noema, EmalexSpeakers' Bureau: Alkermes, Janssen, Otsuka, AxsomeNo medication is FDA approved for stutteringIf you would like to learn more about the Orpheus Study and how to participate, click here: https://www.orpheusstudy.com/WSN

1:45 Labiotech.eu news4:02 PsychoGenics20:56 Destiny Pharma36:30 QureTech Bio54:41 AiCuris70:45 JLLThis week, we have three interviews on the theme of antimicrobial resistance (AMR), to mark World Antimicrobial Awareness Week. We spoke with Holger Zimmermann, CEO of anti-infectives company AiCuris; Neil Clark, CEO of Destiny Pharma, and Fredrik Almqvist, co-founder of QureTech Bio.We also have an interview with the chief scientific officer at PsychoGenics, Mark Varney. We also have our weekly contribution from global commercial real estate services company JLL, with Travis McCready. Next week, we will be moderating a webinar on the microbiome, hosted by our sister company IN-PART. You can register here.World Antimicrobial Awareness WeekAs a result of drug resistance, antibiotics and other antimicrobial medicines may become ineffective and infections become increasingly difficult or impossible to treat. A global action plan to tackle the growing problem of resistance to antibiotics and other antimicrobial medicines was endorsed at the 68th World Health Assembly in 2015. A key objective of the plan is to improve awareness and understanding of AMR through effective communication, education and training.World Antimicrobial Awareness Week is a global campaign to improve awareness and understanding of AMR. Emyria commences US preclinical program with PsychoGenicsEmyria Limited, a clinical stage biotech, is working with PsychoGenics, a specialist neuroscience preclinical drug discovery and contract research organization (CRO). Emyria and partner, the University of Western Australia, will start by screening five novel MDMA analogs from their proprietary library using PsychoGenics' advanced drug discovery platform, SmartCube. SmartCube employs computer vision and artificial intelligence (AI) to extract and analyze behavioral and physiological data from mice. These data can help predict the clinical effects of new drug compounds by comparing the novel drug's effects to reference drug libraries. The automated testing platform offers an effective approach to the discovery and development of the next generation of breakthrough treatments for neurological disorders and can significantly reduce the time and cost to reaching approved Investigational New Drug status. PsychoGenics and Emyria have agreed to work collaboratively (at their own costs) in the initial phase, before exploring drug discovery and commercialization partnership models. PsychoGenics's specialist drug screening platforms have been used in shared-risk partnerships with major pharmaceutical companies, including Sunovion and Roche, resulting in the discovery of several novel compounds now in clinical trials or advanced preclinical development. A successful partnership with Emyria could accelerate the development of Emyria's novel MDMA-inspired drug candidate library, built with the University of Western Australia, into new treatments for severe neuropsychiatric disorders. PsychoGenics has successfully identified novel treatment candidates for serious and complex neuropsychiatric disorders via its proprietary SmartCube platform as well as formed innovative partnerships with major Pharmaceutical companies.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with us

  In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about novel agents in development for Major Depressive Disorder or MDD. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-MDD. Learning Objectives: After completing this educational activity, you should be better able to: Describe novel mechanisms of action of agents under investigation for the treatment of depression Explain the potential implications of novel rapid-acting and multi-modal agents in optimizing outcomes for patients with unipolar depression Integrate newly available options for depression into clinical practice Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva   IntervieweeVladimir Maletic, MD, MS Clinical Professor of Psychiatry, University of South Carolina School of Medicine, Greenville, SC Consultant/Advisor: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda   Pre-Interview AuthorSabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.   The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Sage Therapeutics, Inc. Released: September 26, 2022     CME/CE credit expires: September 26, 2025

In this episode, Dr. Andrew Cutler interviews Dr. Karl Doghramji on best practices for the treatment and management of insomnia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Sleep Learning Objectives: After completing this educational activity, you should be better able to: Utilize assessment tools in the diagnosis of insomnia Address challenges in the pharmacologic treatment of insomnia Implement evidence-based pharmacological treatments for insomnia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.  Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content were required to disclose all relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD  Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Carlsbad, CAConsultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris IntervieweeKarl Doghramji, MDProfessor, Department of Psychiatry & Human Behavior; Associate Professor, Departments of Neurology and of Medicine; Medical Director, Jefferson Sleep Disorders Center; Program Director, Fellowship in Sleep Medicine; Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PAResearch/Grant: Harmony, Inspire Consultant/Advisor: Axsome, Eisai, Jazz, Harmony, Idorsia, Imbrium, Inspire Stockholder: Merck Pre-Interview AuthorSabrina K. Bradbury-Segal, PhDMedical Writer, Neuroscience Education Institute, Carlsbad, CANo financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency, and strategies for understanding and reducing implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Eisai. Released: August 31, 2022          CE credit expires: August 31, 2025

My guest today is Jihad “JR” Rizkallah, Director, MSLs at Sunovion. JR discusses MSL Execution Factors based on the book by Kim Perell. JR Shares…

  In today's CME episode, Dr. Andrew Cutler will be interviewing Dr. Leslie Citrome about the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD03 Learning Objectives: After completing this educational activity, you should be better able to: Recognize the safety and efficacy of VMAT2 inhibitors for the treatment of tardive dyskinesia Individualize treatment regimens for patients with tardive dyskinesia, utilizing FDA-approved medications Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva   IntervieweeLeslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer, Reviva (options)   Pre-Interview AuthorSabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.   The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: July 27, 2022     CME/CE credit expires: July 27, 2025

In this episode featuring Dr. Selim R. Benbadis, listen in on the causes of epilepsy misdiagnosis, review conditions most commonly misdiagnosed as epilepsy, and discuss diagnosis management of psychogenic (functional) seizures.  Accreditations PHYSICIANS ACCME USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. USF Health designates this live activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. Florida Board of Medicine USF Health is an approved provider of continuing education for physicians through the Florida Board of Medicine.  This activity has been reviewed and approved for up to 0.25 continuing education credits.  Target Audience: All physicians Release Date: 5/23/2022 Expiration Date: 5/23/2023 Relevant Financial Relationships All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships. Selim Benbadis, MD: Advisory Board or Panel for Bioserenity, Ceribell, Eisai, Greenwich, LivaNova, Neurelis, Neuropace, SK life science, Sunovion, Zogenix, National Medical Director for RSC Diagnostic Services (EEG), and Florida Medical Director for Stratus (EEG); Consultant for Bioserenity, Ceribell, Eisai, Greenwich, LivaNova, Neurelis, Neuropace, SK life science, Sunovion, and Zogenix; Grants/ Research Support for Cerebral Therapeutics, Cerevel, Neuropace, Greenwich, SK Life Science, Takeda, Xenon; Speaker's Bureau for Aquestive, Bioserenity, Eisai, Greenwich, LivaNova, Neurelis, SK life science, Stratus, Sunovion, and Zogenix. Claim Credit HERE. Visit cme.tgh.org for other CME opportunities, including live webinars, on-demand videos and local events offered to you by Tampa General Hospital.

In this episode, Dr. Andrew Cutler interviews Dr. Diana Perkins on best practices for shared decision making and patient education. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD02 Learning Objectives: After completing this educational activity, you should be better able to: Educate patients and family members with mood disorders and schizophrenia about the symptoms of tardive dyskinesia Address psychosocial and quality-of-life concerns related to tardive dyskinesia in patients with mood disorders and schizophrenia Include patients, caregivers, and family members in shared decision-making when applicable to optimize patient outcomes before and during of treatment of tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.  Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours   Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva  Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva Interviewee Diana Perkins, MD, MPH Professor, Department of Psychiatry; Medical Director, Outreach and Support Intervention Services; University of North Carolina School of Medicine, Chapel Hill, NC  Consultant/Advisor: Alkermes, Karuna  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies, and strategies for understanding and reducing implicit bias can be found in this can be found in this linked handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: May 27, 2022          CE credit expires: May 27, 2025  

In this episode, Dr. Andrew Cutler interviews Dr. Rajnish Mago on best practices for early detection and screening for tardive dyskinesia. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-TD01 Learning Objectives: After completing this educational activity, you should be better able to: Conduct regular screenings for symptoms of tardive dyskinesia in patients with mood disorders and schizophrenia Employ evidence-based screening tools in the differential diagnosis of tardive dyskinesia, including the Abnormal Involuntary Movement Scale  Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.   Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours   Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships, which were then mitigated prior to the activity being presented. Interviewer Andrew J. Cutler, MDClinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Carlsbad, CAConsultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva  Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva Interviewee Rajnish Mago, MD  Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY  Clinical Assistant Professor, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA  Editor-in-Chief, Simple and Practical Medical Education  No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhDMedical Writer, Neuroscience Education Institute, Carlsbad, CANo financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and implicit bias can be found in this downloadable handout. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences. Released: March 23, 2022          CE credit expires: March 23, 2025

In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on best practices for switching antipsychotics. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Switch Learning Objectives: After completing this educational activity, you should be better able to: Understand the relevance of receptor binding properties and pharmacokinetic profiles when switching antipsychotics Follow evidence-based guidelines when switching antipsychotics Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.  Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours   Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships, which were then mitigated prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Stephen M. Stahl, MD, PhD, DSc (Hon.)  Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK Director of Psychopharmacology Services, California Department of State Hospitals, Sacramento, CA Grant/Research: Acadia, Avanir, Braeburn, Intra-Cellular, Ironshore, Lilly, Neurocrine, Otsuka, Shire, Sunovion Consultant/Advisor: AbbVie, Acadia, Alkermes, Allergan, Arbor, Axovant, Axsome, Celgene, ClearView, Concert, EMD Serono, Eisai, Ferring, Impel, Intra-Cellular, Ironshore, Janssen, Karuna, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Relmada, Sage, Servier, Shire, Sunovion, Takeda, Taliaz, Teva, Tonix, Tris, Vifor Speakers Bureau: Acadia, Lundbeck, Otsuka, Perrigo, Servier, Sunovion, Takeda, Teva, Vertex Board Member: Genomind Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and implicit bias can be found in this downloadable handout. Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies. Released: January 26, 2022          CE credit expires: January 26, 2025          

In this episode, Dr. Andrew Cutler interviews Dr. Joseph Goldberg on the management of metabolic side effects associated with antipsychotics.  Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MET  Learning Objectives: After completing this educational activity, you should be better able to: Differentiate antipsychotic medications based on risk for metabolic side effects Monitor patients for metabolic side effects Implement management strategies to address metabolic side effects  Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   NEI designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest minimum score of 70% is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): application-based contact hours Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™  Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.  Disclosures: All individuals in a position to influence or control content were required to disclose any relevant financial relationships, which were then mitigated prior to the activity being presented.  Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris  Interviewee Joseph F. Goldberg, MD   Clinical Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY Consultant/Advisor: BioXcel, Intra-Cellular, Lundbeck, Otsuka, Sunovion Speakers Bureau: Allergan/Abbvie, Intra-Cellular, Sage, Sunovion Royalties: American Psychiatric Publishing, Cambridge University Press Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture  Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies.  Released: December 22, 2021          CE credit expires: December 22, 2024    

Chris Gish has over 30 years of experience in the biopharmaceutical industry in sales and commercial leadership roles. He describes sales rep 3.0, how the customer and industry play a role in its evolution, and the skills and competencies needed to become a sales rep 3.0. We discuss technology, alignment, what pharma organizations would need to do to enable this new role, and the barriers preventing the set-up of the sales 3.0 ecosystem. Tune in as we chat about the importance of the sales rep in modern and future pharma and what we can expect ahead in the years to come.   IN THIS EPISODE:   [03:18] What does Chris mean by sales rep 3.0 and the evolution of the sales rep over the years. [05:25] The role of the pharma customer in the evolution of sales rep 3.0.  [07:08] The skills and competencies a sales rep needs to become a sales rep 3.0. [11:17] The timeline to set up a sales rep 3.0 ecosystem and the barriers to doing so. [15:29] The importance of the sales rep in the future of the pharma industry.   KEY TAKEAWAYS:   Effective promotion and selling in the pharmaceutical space are about effective communication.  Sale rep 3.0. is about how the traditional selling role, behaviors, and competencies will evolve as our communication continues to change. Pharma must keep up with customers' changing preferences and must hire and train for new skills.   LINKS MENTIONED:   Axtria   https://www.axtria.com   Chris Gish on LinkedIn:   https://www.linkedin.com/in/chrisgish/   BIO:   Chris has over 30 years of experience in the pharmaceutical industry across sales and commercial functions. He has held multiple leadership positions, heading sales divisions for large sales teams at Pfizer and Sunovion and at two startup companies, Alder Bio and TherapeuticsMD. At Sunovion, he grew the company's flagship asset, Latuda, into a blockbuster billion-dollar brand. Chris also worked at Pfizer for 21 years with roles in Sales, Marketing, and Training, culminating in  leading all promotion assets, including digital and personal. He currently works in Leadership Development, Coaching, and Sales Force Effectiveness as Principal Consultant at GishGroup and a senior consultant at Accelerated Leadership Group.

In this episode, Dr. Andrew Cutler interviews Dr. Roger McIntyre on best practices for using adjunctive treatment for major depressive disorder. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MDD Learning Objectives: After completing this educational activity, you should be better able to: Discuss earlier identification of partial response to anti-depressants and advantages to implementing augmentation strategies sooner to improve treatment outcomes Increase awareness about evidence-based adjunctive treatments that are FDA-approved for depression Examine the pharmacological profiles of approved adjunctive atypical antipsychotic treatments in terms of how they relate to therapeutic benefits and adverse reactions Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this online live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. CME/CE Credit Types. The following are being offered for this activity: Nursing (ANCC): 1.0 contact hour Pharmacy (ACPE): 1.0 application-based contact hour Physician (ACCME): 1.0 AMA PRA Category 1 Credit ™ Physician Assistant (AAPA): 1.0 Category 1 CME credit Psychology (APA): 1.0 CE credit Social Work (ASWB-ACE): 1.0 ACE CE credit Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for 1.0 AMA PRA Category 1 Credit ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Potential conflicts of interest are identified and resolved prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris  Interviewee Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada Grant/Research: CIHR/GACD/National Natural Science Foundation of China Consultant/Advisor: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda Speakers Bureau: AbbVie, Bausch Health, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Neurocrine, Novo Nordisk, Otsuka, Pfizer, Purdue, Sunovion, Takeda  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture Support: This activity is supported by an unrestricted educational grant from Otsuka and Lundbeck. Released: October 21, 2021          CE credit expires: October 21, 2024    

In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer on best practices and strategies for improving clinician and patient communication, medication adherence, and collaboration in the community when it comes to treating schizophrenia. Optional CE Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click https://nei.global/POD21-Schiz Learning Objectives: After completing this educational activity, you should be better able to: Demonstrate strategies that involve patient and caregivers in shared informed decision-making for treatment goals Discuss the role of social aspects of community and behavioral health settings on patient experiences and treatment outcomes Address best practices for the use of telemedicine when monitoring treatment for schizophrenia and the use of LAIs Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CE credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.25 continuing education hours of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Intra-Cellular, Neurocrine Speakers Bureau: Acadia, Alkermes, Intra-Cellular, Neurocrine, Noven, Otsuka, Sunovion, Teva Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture Support: This activity is supported by an unrestricted educational grant from Otsuka and Lundbeck. Released: September 23, 2021          CE credit expires: September 23, 2024

A BIAL assinou um acordo de licenciamento exclusivo com a farmacêutica norte-americana Sunovion Pharmaceuticals para a comercialização do filme sublingual de apomorfina na União Europeia, Espaço Económico Europeu e no Reino Unido.

In this episode, Dr. Andrew Cutler interviews Dr. Leslie Citrome on some of the challenges that clinicians face when using traditional methods for the treatment of schizophrenia. They discuss the most current research on the development of TAAR1 agonists as a novel class of psychotropic medication for the treatment of schizophrenia. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD21-TAAR1  Learning Objectives: After completing this educational activity, you should be better able to: Describe the challenges with traditional methods of treating schizophrenia Discuss the development of TAAR1 agonists as new class of psychotropic medication for the treatment of schizophrenia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as providers of “formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie, Acadia, Alkermes, Allergan, Astellas, Avanir, Axsome, BioXcel, Cadent Therapeutics, Eisai, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Relmada, Sage, Shire, Sunovion, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sage, Shire, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture  Support: This activity is supported by an unrestricted educational grant from Sunovion Pharmaceuticals Inc. Released: July 29, 2021 CME credit expires: July 29, 2024

John has spoken to some of the Highest Performing organizations such as Microsoft, Hitachi, Intel, Cisco, Mercedes-Benz, BMW, Goodyear, Chevron, Lowe’s, Marriott, Wyndham Hotels, Hilton, Penske Racing, Rawlings, LA Kings, Sprint, Motorola, Merrill Lynch, Mass Mutual, Capital Group, Bank of America, Wells Fargo, GE Capital, American Hospital Association, Merck, Sunovion, Reach Air, Adecco, Gillette, McDonald's, and Million Dollar Round Table.​John’s presentations provide a contagious attitude of thankfulness that he calls Glad To Be Here®. His energizing delivery inspires high performance through a focus on a purpose larger than self. John shares the Blue Angels’ practical model for living out his message that works in organizations outside the elite flight squadron.John consistently performed in an extreme, high-stakes environment, flying at speeds of more than 500 miles per hour and in formations as close as 18 inches. To survive those circumstances, he relied on a culture of high trust and leadership that turned inherently unforgiving flights into extraordinary experiences. He employs those intense realities as a metaphor to motivate teams to reach for their highest potential and empower organizations to sustain excellence under dynamic change.John’s post-Naval experiences as an entrepreneur and a Sloan Fellow at the Stanford Graduate School of Business put him in a unique position to reverse-engineer the culture of excellence and teamwork found in the Blue Angels. He has created a framework and a methodology that inspires greatness while propelling others on their own journey to high performance.John graduated from the U.S. Naval Academy with a degree in mechanical engineering. He was a defensive back for the Midshipmen, playing in two bowl games and helping Navy to one of the best four-year records in football history. As a pilot, John was a “Top Ten Carrier Pilot” six times before becoming a Marine instructor pilot and a Blue Angel. He holds a master’s degrees in business management, from the Stanford Graduate School of Business (as a Sloan Fellow); international policy studies, Stanford University; and strategic studies, from the Naval War College.In 2011 John founded the Glad To Be Here Foundation. John donates 10% of his net speaking fees to charities through the foundation, working with every client to donate 5% to charities of their choosing. Through the Foundation, more than 100 global charities have received $1M in donations. It’s part of John’s mission to connect a shared “purpose larger than self” with every organization.Learn more about John on JohnFoleyinc.com and GladToBeHere.com. Connect with him on Facebook, Instagram, Twitter, LinkedIn, or YouTube.

In this episode, you'll meet James Rawls, PharmD, Vice President and Head of Global Regulatory Affairs at Sunovion Pharmaceuticals. James shares his incredible story of growth within Regulatory Affairs and—importantly—how he sees the diversity and inclusion landscape evolving in the pharmaceutical industry. What can companies do now to promote and support equal opportunity and access for all? What can industry pharmacists do to propel change? And how does James compare his Blackjack strategy to his career decisions? Get answers to these questions and more by listening in!

Dr. Jessica Whelan, family psychiatric nurse practitioner discusses why the holiday season can be particularly challenging for people living with mental health conditions like bipolar I disorder, the difference between holiday blues and bipolar I disorder, and a treatment option people living with bipolar I disorder can discuss with their doctors. Visit www.vraylar.com to learn more including additional safety information. Dr. Jessica Whelan, DNP, BA, APRN, FPMHNP-BC, RN-BC. Dr. Jessica Whelan has extensive experience in the mental health field and has served as a speaker and advisory board member in the areas of nursing leadership, psychopharmacology, bipolar disorder, major depressive disorder, attention deficit disorder, schizophrenia, tardive dyskinesia, pseudobulbar affect, binge eating disorders, autism spectrum disorders, psychopharmacogenomics, epigenetics as well as genetic testing, to name a few. Dr. Whelan is the owner and CEO of a national network of clinicians with Holon Inclusive Health System and adjunct faculty at Maryville University. She supports multiple universities to provide clinical mentorship for medical and nurse practitioner students. She received her Bachelor of Arts from the University of Missouri Columbia and her Bachelor of Science in Nursing degree from Goldfarb School of Nursing at Barnes Jewish College in St. Louis. She received her Master of Science in Nursing from the University of Missouri Columbia and her Doctorate in Nursing Practice at the University of Missouri St. Louis. Her Master’s project consisted of an appraisal of literature regarding NMDA receptor antagonism in the positive and negative symptoms of schizophrenia, and her doctoral project was an evaluation of nurse practitioner led care in psychiatry in comparison to care led by a psychiatrist. She has assisted in activities such as development of mental health Intensive Outpatient Programming as well as clinical documentation to prepare inpatient psychiatric units for Joint Commission Accreditation. Forms that have been developed specifically by her at each of these facilities have been recognized by the Joint Commission as some as the best in the field. She is published in peer reviewed journals such as the Journal of the American Association of Nurse Practitioners. As a nurse she has worked in multiple areas including community mental health, inpatient psychiatric units including adult, acute adult, geriatric, and child and adolescents. In addition to her extensive experience in psychiatry, she has also worked as a nursing supervisor and as part of an acute care float team gaining experience on multiple inpatient medical units. Despite her own struggles with autism, throughout her training and career, she has received several scholarships, honors, and awards. Her most recent award was given from the University of Missouri St. Louis, where she served as an honorary adjunct faculty member through 2019, for her dedication as a Preceptor. She is a policy and political advocate and participates in multiple organizations to support relevant healthcare legislation. In 2019, she was recently recognized and published by the American Nurses Association as part of their Year of Advocacy. Jessica also is recognized as an industry and national thought leader and has been invited to be an advisory board member for psychiatric research and development companies such as Sunovion, Allergan, Abbvie, Teva, and Avanir.

Neurodegenerative disorders have become increasingly prevalent today and can often be accompanied by dementia and other neuropsychiatric conditions such as psychosis. It is important to be able to differentiate psychosis that is associated with various types of dementia, while this can be challenging to clinicians. However, there are several existing and novel therapeutics that can manage dementia-related psychosis. In this episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo on the practical strategies for the management of dementia-related psychosis. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-DemPsychosis Learning Objectives: After completing this educational activity, you should be better able to: Describe the clinical presentation of psychosis in dementia Employ pharmacological treatment strategies to ameliorate psychosis in patients with dementia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by a PhD specializing in neurodegenerative diseases to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Laxman Bhagwan Bahroo, DO Associate Professor and Residency Program Director, Department of Neurology; Director, Botulinum Toxin Clinic; MedStar Georgetown University Hospital Pasquerilla Healthcare Center, Washington, DC Consultant/Advisor: AbbVie, Acadia, Acorda, Allergan, Amneal, Neurocrine, Revance, Sunovion, US World Meds Speakers Bureau: AbbVie, Acadia, Acorda, Adamas, Allergan, Amneal, Ipsen, Neurocrine, Sunovion, UCB, US World Meds Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture  Support: This activity is supported by an unrestricted educational grant from Acadia Pharmaceuticals. Released: December 14, 2020     CME credit expires: December 14, 2023

Despite increasing evidence that bipolar disorders often emerge in adolescence, only about half of adolescents with a bipolar disorder receive mental health care. Research has shown that an early onset of a bipolar disorder, concomitant with a poor diagnosis and lack of treatment, can have lifelong devastating effects for the patient. Adults and younger people who initially exhibit symptoms only of depression may later develop bipolar disorder. The risk of depression turning into bipolar disorder is estimated at 10 percent or less in adults but appears to be as high as 20–40 percent in children and adolescents. In this episode, Dr. Neera Ghaziuddin answers many questions regarding how to better diagnosis and treat pediatric bipolar disorder, and depression with mixed features in the pediatric population. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-PedBip Learning Objectives: After completing this educational activity, you should be better able to: Discuss challenges to diagnosing bipolar disorder in the pediatric population (e.g. adolescents) Define the concept of “mixed features” according to different diagnostic criteria Improve the differential diagnosis of depression with mixed features (DMX) in children and adolescents Utilize evidence-based therapies in the treatment of pediatric patients presenting with DMX Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in pediatric psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Neera Ghaziuddin, MD, MRCPsych Professor, Child and Adolescent Psychiatry Unit, Department of Psychiatry, University of Michigan Medical School, Ann Arbor, MI No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found at https://nei.global/culture. Support: This activity is supported by an unrestricted educational grant from Sunovion. Released: December 3, 2020     CME credit expires: December 3, 2023

Tardive dyskinesia (TD) is a movement disorder characterized by involuntary movements of the tongue, lips, face, trunk, and extremities that occur in patients treated with dopamine receptor blocking agents (DRBAs). Patients can have symptoms that persist for months, years, or even permanently. Greater awareness about risk factors and which agents may be associated with higher likelihood of developing TD is critical to reduce the prevalence of this disorder. Understanding the most effective novel treatment approaches to TD is also important. In this episode, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the current best practices in the diagnosis, recognition, and treatment of tardive dyskinesia.  Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click https://nei.global/POD20-TD  Learning Objectives: After completing this educational activity, you should be better able to: Identify the clinical presentation of tardive dyskinesia Implement treatment strategies for the management of tardive dyskinesia  Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.  Peer Review: The content was peer-reviewed by a PhD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris  Interviewee Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Allergan, Intra-Cellular Therapies, Neurocrine Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Neurocrine, Otsuka, Sunovion, Teva  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no relevant financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Neurocrine Continental, Inc.  Released: November 19, 2020          CME credit expires: November19, 2023

Integrative Treatments for Psychiatric Conditions in Primary Care Evaluation and Credit: https://www.surveymonkey.com/r/MedChat20   Target Audience   Behavioral and mental health providers, primary care physicians, advanced providers and psychiatrists.   Statement of Need Mental health issues including anxiety/depression and chronic stress are becoming a serious health issues and not treated can lead to more serious health problems. The most conventional treatment for these diagnoses and other behavioral health diagnoses is allopathic therapies and counseling. As more patients are wanting complementary and alternative medicine (CAM) for medical issues as well as behavioral health issues it is important for providers to have the latest information CAM treatments - applications and effectiveness. Objectives At the conclusion of this offering, the participant will be able to: Define complementary and alternative medicine (CAM) List complementary and alternative medicine (CAM) therapies used in behavioral medicine. Describe the application and effectiveness of CAM in behavioral medicine. Moderator John J. Wernert, M.D., MHA, DLFAPA Executive Medical Norton Behavioral Medicine Speaker Christopher D. Bojrab, M.D., DFAPA President Indiana Health Group Carmel, Indiana   Speaker Disclosure The speaker has the following conflicts of interest to disclose:  Consultant and Speakers Bureau – Allergan, Assures/Myriad, Neurocrine, Otsuka, Sunovion, Takeda and Teva.   Moderator and Planner Disclosures  The moderator and planners for this activity have no potential or actual conflicts of interest to disclose. Commercial Support  This activity has not received commercial support.   Continuing Education Credits  American Medical Association   Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   Date of Original Release | November 2020 Course Termination Date | December 2021   Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org   Resources for Additional Study    Anxiety and Depression Association of America; https://adaa.org/finding-help/treatment/complementary-alternative-treatment.   National Alliance on Mental Illness, https://www.nami.org/About-Mental-Illness/Treatments/Complementary-Health-Approaches.   Wang, Claudia, et. al., Complementary and alternative medicine use among children with mental health issues: results from the National Health Interview Survey, Complementary and Alternative Medicine (2018) 18:241. https://bmccomplementmedtherapies.biomedcentral.com/articles/10.1186/s12906-018-2307-5  

Opioid addiction, abuse, and overdose have all grown to epidemic proportions in the United States as well as worldwide in recent years—such information is no longer up for debate. With an estimated 400,000 persons using illicit opiates each month, and another 4 million reporting use of prescription pain relievers for nonmedical purposes, in the United States alone, the debate now surrounds how best to treat those individuals suffering from opioid use disorder (OUD). In the past few years, there has been growing evidence for the efficacy of medication assisted therapy (MAT) for the treatment of OUD. However, there are still many challenges. Questions arise such as: What sort of training does a prescriber need to undertake in order to be able to prescribe medications for the treatment of OUD and how is this a barrier to treatment? How are the billing procedures for MAT challenging for clinicians who are prescribing? In this CME NEI Podcast, Dr. Larissa Mooney answers these questions and more on MAT for OUD. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Describe the challenges to treating opioid use disorder (OUD) with medication assisted therapy (MAT) Explore treatments designed to optimize cessation of opioid addiction Discuss legal barriers and insurance barriers to treatment of OUD  Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MDs and DOs: NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: the ANCC and NCCPA accept organizations accredited by the ACCME as “providers of formally approved continuing education hours” (ANCC) and “Category 1 CME” (NCCPA). The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Faculty Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Faculty Interviewer / Author Larissa J. Mooney, MD Associate Clinical Professor, Department of Psychiatry and Biobehavioral Sciences; Director, Addiction Medicine Clinic; University of California, Los Angeles Semel Institute for Neuroscience and Human Behavior, Los Angeles, CAChief, Substance Use Disorders Clinic, VA Greater Los Angeles Healthcare System, Los Angeles, CA No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Alkermes.  Released: Sept 30, 2020          CME credit expires: Sept 30, 2023   Need to fulfill your CME credits? Join us virtually at NEI Max! and earn up to 28.75 CME credits. Check out with promo code PODCAST09 to get 10% off.

In the first episode of our second season, Peter Brenders, Founder & President of Kontollo Health, talks with Lisa Mullett, General Manager of Sunovion, about motivating teams and adapting to a virtual landscape. Get on the email list at healthbiz.substack.com

Evaluation and Credit: https://www.surveymonkey.com/r/MedChat18   Target Audience            This activity is targeted toward Primary care specialties and psychiatrists. Statement of Need Promising research is being conducted on psychedelics for the treatment of psychiatric disorders.  Providers should be aware of emerging treatments. This podcast will address the research base and clinical use of psychedelics in the United States. Providers will be informed on the potential for use in practice in the future. Objectives At the conclusion of this offering, the participant will be able to: Review the history of psychedelics. Discuss the chemical and pharmacological properties of psychedelics. Describe the clinical use of psychedelics in the United States, including clinical trials.   Moderator John J. Wernert, M.D., MHA, DLFAPA Executive Medical Norton Behavioral Medicine   Speaker Christopher D. Bojrab, M.D., DFAPA President Indiana Health Group Carmel, Indiana   Speaker Disclosure The speaker has the following conflicts of interest to disclose:  Consultant and Speakers Bureau – Allergan, Assures/Myriad, Neurocrine, Otsuka, Sunovion, Takeda and Teva. Moderator and Planner Disclosures  The moderator and planners for this activity have no potential or actual conflicts of interest to disclose. Commercial Support  This activity has not received commercial support.   Continuing Education Credits American Medical Association   Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians.   Designation Norton Healthcare designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   Kentucky Board of Nursing Kentucky Board of Nursing (KBN) Approved Provider: Norton Healthcare, provider number 4-0002-12-20-245. The program has been approved by Norton Healthcare for 0.6 contact hours which expires 12/31/2020. KBN approval of a continuing education provider does not constitute endorsement of program content. Nursing participants must attest to the number of hours of attendance and complete the evaluation to receive contact hours. For more information related to nursing credits, contact Sally Sturgeon DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org   Date of Original Release | September 2020 Course Termination Date | December 2021  Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org     Resources for Additional Study    Chi, Tingying and Gold Jessica A., A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses, Journal of the Neurological Sciences, Volume 411, 15, April 2020. https://www.sciencedirect.com/science/article/pii/S0022510X20300514?via%3Dihub  Krediet, Erwin, et.al., Reviewing the Potential of Psychedelics for the Treatment of PTSD, International Journal of Neuropsychopharmacology, March 20, 2020. https://academic.oup.com/ijnp/article/23/6/385/5805249 Romeo, Bruno, et. al, Efficacy of psychedelic treatments on depressive syndromes: A meta-analysis, Journal of Psychopharmacology, May 25, 2020.  https://journals.sagepub.com/doi/10.1177/0269881120919957   

Schizophrenia is a chronic and debilitating disorder that creates a substantial burden not only for patients but also for their families. The high rates of treatment resistance, relapse rates, and incidence of adverse side effects in patients with schizophrenia suggest that a major treatment gap continues to exist. Given the high rates of treatment resistance, novel strategies and therapeutic approaches beyond D2 receptor blockade are being intensively studied. What are some of these novel approaches? How effective are they in the treatment of schizophrenia? What medications are available, or emerging that target neurotransmitters systems beyond dopamine? In this podcast episode, Dr. Jonathan Meyer and Dr. Leslie Citrome discuss some of the ground-breaking work in this field, and how you can better treat patients with schizophrenia. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Describe clinical advances in our understanding of schizophrenia Describe novel treatments for schizophrenia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee / Author Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, Vanda Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Lilly, Johnson & Johnson, Merck, Pfizer Interviewee / Author Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Allergan, Intra-Cellular Therapies, Neurocrine Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Neurocrine, Otsuka, Sunovion, Teva Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout. Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies. Released: July 23, 2020          CME credit expires: July 23, 2023

The years 2019-2020 brought to us coronavirus disease 2019 (COVID-19), resulting in an unprecedented global pandemic. Emerging data, historical studies, and expert opinion point to a tremendous impact of COVID-19 on the development and exacerbation of psychiatric issues. This issue is compounded by the fact that access to mental health care services may be limited during this time of crisis. There is a critical need for mental health care providers to be prepared and educated to best serve the psychiatric needs of patients affected, either directly or indirectly, by the COVID-19 pandemic. There are still many questions. What are the psychological consequences of so many people losing their jobs, and so many businesses shutting down? What are some healthy coping strategies for parents to model at home, to protect their children’s mental health during this pandemic? In this CME NEI podcast episode, Dr. McIntyre answers these questions, and much more.  Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.  Learning Objectives: After completing this educational activity, you should be better able to: Discuss the psychological, economic, and sociological implications that COVID-19 has had on mental health Examine the impact of COVID-19 on a variety of mental health issues Explore existing and novel strategies for continuing mental health care during a global pandemic such as COVID-19 Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. Peer Review: The content was peer-reviewed by a PhD-PMHNP specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Faculty Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Faculty Interviewee / Author Roger S. McIntyre, MD, FRCPC   Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada Grant/Research: CIHR/GACD/Chinese National Natural Research Foundation, Stanley Medical Research Institute Consultant/Advisor: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda Speakers Bureau: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported by an unrestricted educational grant from Alkermes.  Released: July 9, 2020          CME credit expires: July 9, 2023  

Scott Hylla, Director; Health Systems Scott Hylla is the Director of Health Systems for Sunovion Pharmaceuticals Inc. He has served in various roles spanning a 28 year career in the pharmaceutical industry, most recently in leading the Sunovion Health Systems team in the development and execution of collaborative strategies in the transformational IDN marketplace.Scott has a BS in Biology from St. John’s University and an MBA in Healthcare Management from the Opus College of Business, University of St. Thomas. He is a member of American College of Healthcare Executives and is a corporate participant in the Health Management Academy and Advisory Board.John Marchica, CEO, Darwin Research GroupJohn Marchica is a veteran health care strategist and COO of Darwin Research Group, a health care market intelligence firm specializing in health care delivery systems. He’s a two-time health care entrepreneur, and his first company, FaxWatch, was listed twice on the Inc. 500 list of fastest-growing American companies. John is the author of The Accountable Organization and has advised senior management on strategy and organizational change for more than a decade.John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is a faculty associate in the W.P. Carey School of Business and the College of Health Solutions at Arizona State University and is an active member of the American College of Healthcare Executives.About Darwin Research Group   Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

Methamphetamine is an extremely serious problem in the United States, and it remains one of the most commonly misused stimulant drugs in the world. There are severe psychological, and medical consequences from methamphetamine misuse and abuse. This poses a particular challenge for clinicians treating patients for mental health conditions that are comorbid with substance use disorder (SUD). This is especially challenging when there are also interactions that can alter or influence psychiatric medications used to treat these patients. Questions such as the following arise: Given the high comorbidity of SUD with ADHD, how often should you check drug screens, and what is the threshold for discontinuing the stimulants if tests come back positive? In this podcast episode, Dr. William Sauve’ addresses these concerns, and much more. He also employs strategies to improve communication with patients about being transparent when it comes to using substances. Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Manage the challenges associated with psychiatric treatment of conditions comorbid with substance use disorder Integrate psychiatric drug interactions with methamphetamine use Assess treatments approaches for conditions associated with long-term use of methamphetamines Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.50 continuing education hour of pharmacotherapeutics.  Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Faculty Interviewer Andrew J. Cutler, MD   Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris   Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris Faculty Interviewee William M. Sauvé, MD Regional Medical Director, Greenbrook TMS NeuroHealth Centers, Virginia Speakers Bureau: Avanir  Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported solely by the provider, NEI.  Released: June 8, 2020          CME credit expires: June 8, 2023

Food and beverages interact with certain psychiatric medications to alter their pharmacokinetic properties, resulting in potentially unintended health outcomes. In this podcast episode, Dr. Rajnish Mago describes common food and beverages that interact with psychiatric medication and provides recommendations for avoiding unintended food-drug interactions. Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE.  Learning Objectives: After completing this educational activity, you should be better able to: Describe the effects of food on the bioavailability of certain psychotropic medications Discuss current evidence of the brain-gut connection’s impact on mental health Describe the effects of vitamin C, caffeine, and grapefruit on the pharmacokinetics of certain psychotropic medications  Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics.  Peer Review: The content was peer-reviewed by a PharmD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity.  Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented.  Faculty Interviewer / Author Andrew J. Cutler, MD   Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris   Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris Faculty Interviewee / Author Rajnish Mago, MD Clinical Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Speakers Bureau: Intas Stockholder: Johnson and Johnson  Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout.  Support: This activity is supported solely by the provider, NEI.  Released: May 11, 2020          CME credit expires: May 11, 2023    

What is our current understanding of the gut-brain connection? What is the difference between the microbiome and microbiota? How is dysbyosis of the gut associated with certain psychiatric disorders? In this CME podcast, we address these questions and more in this captivating interview between Dr. Andrew J. Cutler and Dr. Roger S. McIntyre! Optional CME credits / certificate instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Explore the relationship between the brain-gut-microbiome axis and chronic inflammation Discuss current evidence of the brain-gut connection’s impact on mental health Consider potential implications of the gut-brain connection for the treatment of various mental illnesses Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit. Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Faculty Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Alkermes, Allergan, Axsome, Biohaven, Intra-Cellular, Lundbeck, Novartis, Otsuka, Sage, Sunovion, Tris Consultant/Advisor: Acadia, AiCure, Alfasigma, Alkermes, Allergan, Avanir, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Takeda, Teva, Tris Speakers Bureau: Acadia, Alkermes, Allergan, Avanir, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Takeda, Teva, Tris Faculty Interviewee / Author Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology; Head, Mood Disorders Psychopharmacology Unit, University Health Network; University of Toronto, Toronto, ON, Canada Grant/Research: CIHR/GACD/Chinese National Natural Research Foundation, Stanley Medical Research Institute Consultant/Advisor: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda Speakers Bureau: Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, Takeda Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout. Support: This activity is supported solely by the provider, NEI. Released: April 13, 2020          CME credit expires: April 13, 2023

A lot of people think that if you have epilepsy, you were born with it or developed it as a child. But the truth is, 1 in 26 people will be diagnosed with epilepsy in their lifetime. Anyone can develop epilepsy - at any point, at any age. And as the population grows older, more and more adults will develop epilepsy. Nancy Goldfarb is one of those people. Nancy explains what it feels like for her to have a seizure, how her super power is something called an aura, and why the last thing she wants you to do is put a stick in her mouth. To help tell her story, Nancy is joined by her Neurologist and Jefferson University Physician, Dr. Christopher Skidmore. Thank you to our sponsors: Sunovion - A committed partner of the Epilepsy Foundation and TalkAboutIt.org To learn more about Epilepsy Research and how to join a clinical trial, Visit efepa.org/research Credits: Produced by The Epilepsy Foundation Eastern Pennsylvania Post Production by Studio D Podcast Production Additional Resources: https://www.beyondceliac.org/celiac-disease/facts-and-figures/ https://www.joslin.org/info/genetics_and_diabetes.html

Welcome to Season 2 of Health Care Rounds. In this episode, John Marchica speaks with Scott Hylla, Director of Health Systems and Managed Markets with Sunovion Pharmaceuticals. Scott and John discuss the state of pharma-IDN partnerships, pharma attitudes toward ACOs, and the future of industry-provider relations. Key questions include: How does pharma align with integrated health systems (IDNs), and what are IDNs looking for in a partnership? Should pharma partner with ACOs, and if so, why? What are the key trends in health care delivery that drive pharma toward higher-level partnerships? Speaker Bios Scott Hylla is the Director of Health Systems for Sunovion Pharmaceuticals Inc. He has served in various roles spanning a 28 year career in the pharmaceutical industry, most recently in leading the Sunovion Health Systems team in the development and execution of collaborative strategies in the transformational IDN marketplace. Scott has a BS in Biology from St. John’s University and an MBA in Healthcare Management from the Opus College of Business, University of St. Thomas. He is a member of American College of Healthcare Executives and is a corporate participant in the Health Management Academy and Advisory Board. John Marchica is a veteran health care strategist and CEO of Darwin Research Group, a health care market intelligence firm specializing in health care delivery systems. He’s a two-time health care entrepreneur, and his first company, FaxWatch, was listed twice on the Inc. 500 list of fastest growing American companies. John is the author of The Accountable Organization and has advised senior management on strategy and organizational change for more than a decade. John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is a faculty associate in the W.P. Carey School of Business and the College of Health Solutions at Arizona State University, and is an active member of the American College of Healthcare Executives. About Darwin Research Group Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

1. Antiepileptic Drug Clearances during Pregnancy and Clinical Implications for Women with Epilepsy2. AAN Position Statement: Lawful physician-hastened deathIn the first segment, Dr. Derek Bauer talks with Dr. Paula Emanuela Voinescu about her paper on antiepileptic drug (AED) clearances during pregnancy and the relationship between AED serum concentration and seizure frequency. In the second part of the podcast, we are featuring a discussion with Dr. Jason Crowell and Dr. James Russell on the recent AAN position statement regarding lawful physician-hastened death.DISCLOSURES: Dr. Voinescu has received speaker honoraria from SUNOVION, and has received research support from American Academy of Neurology, Susan Spencer Clinical Training Fellowship. Dr. Russell has received funding for travel from the Mexican Academy of Neurology; receives publishing royalties from Neuromuscular Disorders (McGraw-Hill, 2nd ed, 2015) and honorarium for a published article in Continuum Peripheral Neuropathy 2017; has received compensation for market research interviews regarding ALS therapeutics; and has received reimbursement for record review of medical legal proceedings without testimony or document authorship. All other participants report no disclosures.

1. Featured Article: Practice guideline update summary: Efficacy and tolerability of new antiepileptic drugs I: Treatment of new-onset epilepsy2. Lesson of the Week: Functional Disorders This podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the July 10, 2018 issue of Neurology. In the first segment, Dr. Derek Bauer talks with Dr. Jacqueline French about her paper, a summary of a recent practice guideline on the treatment of new-onset epilepsy. In the second part of the podcast, Dr. David Lapides continues the Lesson of the Week discussion on functional disorders with Dr. Jon Stone. DISCLOSURES: Dr. French has served on scientific advisory boards and consulted for the Epilepsy Foundation, Acadia, Acorda, Adamas, Alexza, Anavex, Axcella Health, Biogen, BioPharm Solutions, Cavion, Cerecor, Cerebral Therapeutics, Concert Pharmaceuticals, Covance, CuroNZ, Eisai, Empatica, Engage, Georgia Regents University, Glaxo Smith-Kline, GW Pharma, J&J Pharmaceuticals, Marinus, MonosolRx, Monteris, Nestle-Health Science, Neurelis, Novartis, Otsuka, Ovid, Pfizer, Pfizer-Neusentis, Sage Therapeutics, Shire, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith, Ultragenyx, Xenon Pharmaceuticals, Xeris, Zogenix and Zynerba; has received research support from Alexza, Acorda, LCGH, Eisai Medical Research, LCGH, Lundbeck, Neurelis, Pfizer, SK life sciences, Sunovion, Takeda, UCB, Upsher-Smith, Biogen, NINDS (2U01NS038455-11A1), Epilepsy Foundation, and Epilepsy Study Consortium; has received paid travel to present findings at scientific meetings, present at investigators' meetings, attend advisory boards, or give lectures from Epilepsy Study Consortium, Epilepsy Foundation, International League Against Epilepsy, American Academy of Neurology, American Epilepsy Foundation, Adamas, Biogen, Eisai, Engage, GW Pharma, GSK, Novartis, Otsuka, Ovid, Pfizer, Sage, Sunovion, Takeda, UCB, Ultragenyx, Upsher-Smith, Zynerba, Blackfynn Pfizer, Pfizer-Neusentis, Sage, SK Life Sciences, Sunovion, Takeda, UCB Inc., Upsher Smith,Zogenix, and Zynerba; serves on editorial boards for Lancet Neurology, Neurology Today, and Epilepsy Currents; and serves as President, Epilepsy Study Consortium Chief Scientific Officer, Epilepsy Foundation. Drs. Bauer and Lapides report no disclosures. Dr. Stone receives publishing royalties from UptoDate; runs a free self-help website for patients with functional disorders www.neurosymptoms.org; and carries out regular expert witness work in relation to personal injury and medical negligence.

Show description/summary:1) Qualitative study of burnout, career satisfaction, and well-being among US neurologists in 20162) What’s Trending: gene editing in human embryosThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the October 17, 2017, issue of Neurology. In the first segment, Dr. Pearce Korb talks with Dr. Janis Miyasaki about her paper on burnout, career satisfaction and well-being among US neurologists. In the second part of the podcast, Dr. Jason Crowell focuses his interview with Dr. Shoukhrat Mitalipov on gene editing in human embryos for correction of a pathogenic mutation.DISCLOSURES: Dr. Miyasaki has received honoraria from Davis Phinny Foundation, Sunovion, and NINDS; receives publishing royalties from “Up to Date: Psychogenic Movement Disorders;” has consulted for Cynapsus and GE; has served on a scientific advisory board for Parkinson Society Canada; and has received research support from Allergan, PCORI, and Parkinson Alberta.Dr. Mitalipov holds patents for Primate Totipotent and Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. patent No. 7,972,849), Human Pluripotent Stem Cells Produced by Somatic Cell Nuclear Transfer (U.S. Patent No. 9,546,383), and Methods for Mitochondrial DNA Replacement in Oocytes (U.S. Patent No. 9434921); has patents pending for Metabolic rescue in pluripotent cells from subjects with mitochondrial DNA disease (Application Number: 62192358), Generation of human oocytes by polar body transfer” (Application 62/419,638), and Mitochondrial Replacement in Human Oocytes Carrying Pathogenic Mitochondrial DNA Mutations (Application 62427546); has consulted for Flagship VentureLabs; and has received research support from NIH/NIA, Burroughs Wellcome Fund, and Foundation Leducq.Dr. Korb and Dr. Crowell report no disclosures.

Today in FirstWord:

1) AAN guideline summary: Treatment of restless legs syndrome in adults 2) What's Trending: Interview with Dr. Steven Messé on why acute ischemic stroke patients are not receiving IV tPA3) Topic of the month: Neurology Today story about cases of acute flaccid myelitis spike: What the Center for Disease Control says you should look out forThis podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Fullard interviews Dr. John Winkelman about the AAN guideline summary on the treatment of restless legs syndrome in adults. Dr. Andy Southerland is interviewing Dr. Steven Messé for our “What's Trending” feature of the week about his paper on why are acute ischemic stroke patients not receiving IV tPA. In the next part of the podcast Dr. Ted Burns interviews Drs. Kevin Messacar and Ken Tyler about a Neurology Today story on the topic on cases of acute flaccid myelitis spike: What the Center for Disease Control says you should look out for.DISCLOSURES: Dr. Winkelman serves as Associate Editor for Sleep; serves as an editorial board member of Sleep Medicine and CNS Drugs; received honoraria from serving on the scientific advisory board of Merck Serono, Flex Pharma, UCB, Impax Pharmaceuticals, Pfizer Inc, Lacrima, Luitpold Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, Xenoport, Zeo Inc., Sunovion, Insys, Takeda Pharmaceutical Company Limited, Jazz and Neurogen; receives royalties from the publication of the books: Foundations of Psychiatric Sleep Medicine and Nocturnal Leg Cramps; holds stock options in Flex Pharma; provided expert witness work for ArentFox and CantorColburn; received funding for travel from Novartis and Otsuka; currently performs neurophysiology studies as part of his practice;receives research support from Xenoport, GlaxoSmithKline, UCB, Sepracor, Pfizer Inc, Impax Pharmaceuticals, Purdue, Neurometrix and the NIH.Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review.Dr. Messé received publishing royalties from UpToDate; received compensation from GlaxoSmithKline for consulting on protocol development for a trial of a neuroprotectant in high risk surgery; received research support from GlaxoSmithKline, Bayer Schering Pharma, WL Gore and the NIH.Dr. Ted Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc.Dr. Tyler serves as an Associate Editor for Journal of Neurovirology and Neurology Today; serves as an editorial board member for Annals of Neurology, Apoptosis, JAMA Neurology, Experimental Neurology, Journal of Infectious Disease, Microbial Pathogenesis, Virology, Neurology ALL Current; serves on the scientific advisory board for PML Consortium; is a consultant for Hoffman La Roche; receives royalties from the publication of the books: Handbook of Clinical Neurology and Harrison's Principles & Practices of Internal Medicine; receives research support from the NIH. All other participants report no disclosures.

Welcome to Biotechnology Focus Podcast. I’m your host Shawn Lawrence. We kick things off this week with the release of our latest issue of Biotechnology Focus and as such we thought we should give you our listeners a rundown or sneak peak of all the stories you’d see. As most or our listeners know, there are comprehensive changes to the way the Federal Government supports science and innovation in Canada coming with consultations on Canada’s Innovation Agenda drawing to a close and this issue reaches your desk with this Call to Action in mind, beginning with our cover story on the results from our latest Hot Button Issue Survey. The survey was open to everyone in both the private and public sectors and at all organizational levels, from the c-level right on down. In all, 163 of you got back to us with what you’d like to see from the Innovation Agenda. Under the microscope for many of you was one of the biggest sources of government cash for private sector research and innovation in Canada, the Scientific Research and Experimental Development program or SR&ED’s as they are more commonly known. It was interesting to see how many of you rely on this program, and why many of you feel this program needs not only to be maintained but expanded upon. Be sure to check out this and what other priorities were included in our special report. And for further reading on the SR&ED program, Elizabeth Pringle, the National Life Sciences Industry Lead for Ernst & Young LLP’s Business Tax Incentives Practices, discusses recent changes to the program itself while suggesting more alternatives to strengthening the overall tax credit regime for life science companies in Canada, including looking south of the border for some inspiration. Moreover, she highlights some of the recent CRA programs added to help increase tax claim certainty and reduce the administrative burden of applying for SR&EDs including the Pre-Claim Consultation program which launched on June 29 and the Pre-Claim Review (PCR) pilot project which launched August 2. In addition to underlining your priorities that you’d like to get before As most or our listeners know, there are comprehensive changes to the way the Federal Government supports science and innovation in Canada coming with consultations on Canada’s Innovation Agenda drawing to a close and this issue reaches your desk with this Call to Action in mind, beginning with our cover story on the results from our latest Hot Button Issue Survey. The survey was open to everyone in both the private and public sectors and at all organizational levels, from the c-level right on down. In all, 163 of you got back to us with what you’d like to see from the Innovation Agenda. Under the microscope for many of you was one of the biggest sources of government cash for private sector research and innovation in Canada, the Scientific Research and Experimental Development program or SR&ED’s as they are more commonly known. It was interesting to see how many of you rely on this program, and why many of you feel this program needs not only to be maintained but expanded upon. Be sure to check out this and what other priorities were included in our special report. And for further reading on the SR&ED program, Elizabeth Pringle, the National Life Sciences Industry Lead for Ernst & Young LLP’s Business Tax Incentives Practices, discusses recent changes to the program itself while suggesting more alternatives to strengthening the overall tax credit regime for life science companies in Canada, including looking south of the border for some inspiration. Moreover, she highlights some of the recent CRA programs added to help increase tax claim certainty and reduce the administrative burden of applying for SR&EDs including the Pre-Claim Consultation program which launched on June 29 and the Pre-Claim Review (PCR) pilot project which launched August 2. In addition to underlining your priorities that you’d like to get before government, this issue also spotlights what makes Canadian biotech great, and highlights some of the areas we can become stronger. It starts with Wayne Schnarr’s roundup piece, “Looking for success stories in Canadian Healthcare.” As he explains, measuring success in Canada’s health technology sector is no easy task, and varies depending on one’s perspective. His article looks at the Canadian biotech landscape from the viewpoint of an investor and reminds us that they judge successful companies differently than government, economic development offices and the companies themselves. With the investors wish list in mind, he highlights some Canadian companies to keep an eye on, including one who is featured later in this podcast Cynapsus. Unfortunately, investors may have missed the boat on that company, but we’ll get to that later. Next in our editorial lineup TO Health’s Ella Korets-Smith, Montreal In Vivo’s Frank Beraud and Teralys Capital’s Cedric Bisson cowritten piece “Canada Poised to be best in the World in Life Sciences Sector” recognizes Canada as a world class biotech hub whose greatest strength is working together to promote our successes in this arena. However, they add that there is still room to grow, and we must begin by looking to other jurisdictions for best practices especially in areas such as venture capital investment. Next, Zymeworks lead man Ali Tehrani, no stranger to success, and perhaps the type of entrepreneur we need to hear more ideas from on how to improve the industry, asks the question why isn’t Canadian biotech with all its great science, visionary entrepreneurs and angel investors, ranked among the best in the world. In addition to posing the question, he endevors to answer it, offering three near and long-term solutions. We have all this and more packed into this issue, so be sure to sign up for our digital edition service to see this issue and past issues as well. Story 2 Our first news story this week is a science story, and features a breast cancer research breakthrough. Specifically, a team of researchers in Canada have discovered that mutations found outside of genes that accumulate in estrogen receptor positive breast tumours throughout their development act as the dominant culprits that drive the disease. The multi-institutional research team collaborated with the Princess Margaret Genomics Centre and Bioinformatics group to analyze changes in the DNA sequence that accumulate in patients’ tumours with respect to the epigenetic identity of estrogen receptor-positive breast cancer cells.. The research, published online in Nature Genetics, focuses on the most common type of breast cancer, estrogen receptor positive, and was led by principal investigator Dr. Mathieu Lupien, senior scientist, Princess Margaret Cancer Centre, University Health Network and associate professor in the Department of Medical Biophysics, University of Toronto. His team investigated acquired mutations found outside of genes through the power of epigenetics, and identified that functional regulatory components can be altered to impact the expression of genes to promote breast cancer development. Dr. Lupien discusses the study in the following audio provided by UHN Toronto Dr.Lupien’s research builds on a previous study that identified why 44 known genetic variations increased breast cancer risk (Nature Genetics, Sept. 23, 2012). He adds that the convergence of more knowledge about inherited risk variants and the role of acquired mutations should readily enable translating the science into more precise clinical tests to diagnose and monitor patients. His work was funded by The National Cancer Institute at the National Institute of Health, The Princess Margaret Cancer Foundation, Canadian Cancer Society, Susan G. Komen Foundation, the Ontario Institute for Cancer Research, the Canadian Institute of Health Research and a Movember Rising Star award from Prostate Cancer Canada. Story 3 Enerkem Inc., a Canadian headquartered waste-to- biofuels and chemicals producer, has obtained certification from the International Sustainability and Carbon Certification (ISCC) system and will now be able to begin biomethanol production at its Biofuels full-scale facility in Edmonton,AB. According to the company the third-party certification confirms that Enerkem meets high ecological and social sustainability requirements. Enerkem makes biofuels and renewable chemicals from non-recyclable municipal solid waste. The company owns a full-scale commercial facility in Alberta as well as a demonstration plant and a pilot facility in Quebec. The company is also developing additional biorefineries in North America and globally, based on its modular manufacturing approach. With the certification, the Edmonton biorefinery is now the first ISCC certified plant in the world to convert municipal solid waste into biomethanol. Story 4 In business news, Laval’s ProMetic Life Sciences has entered into a binding agreement to acquire Belleville, Ontario’s Telesta Therapeutics in an all share transaction. By way of a plan of arrangement under the Canada Business Corporations Act, ProMetic will acquire all of the share capital of Telesta at a share price of $0.14 payable in ProMetic common shares. The number of common shares to be issued by ProMetic will be based on the volume-weighted average closing price (VWAP) of ProMetic’s common shares for the five (5) trading days prior to the closing date of the acquisition. According to ProMetic, the deal gives the company the opportunity for further integration of its manufacturing capabilities and longer term capacity expansion in a 150,000 sq. ft. facility in Belleville, ON. At the same time it gives  ProMetic  a significant foothold in Ontario, consolidating its presence as a major player in the Canadian market. Completion of the deal is subject to the approval of Telesta’s shareholders and a number of customary closing conditions including court and regulatory approvals (such as the approval of the Toronto Stock Exchange). The acquisition is expected to close in early November, 2016. Story 5 Rapid infectious disease test developer bioLytical Laboratories has filed two patent applications with the U.S. Patent and Trademark Office relating to its multiple colour rapid detection assay systems for the detection of antibodies to pathogens including Zika and other flaviviruses. The two new patent applications are based on the company’s INSTI platform and describe methods and kits allowing either simultaneous or sequential detection of different antibody classes to multiple pathogens using a single sample of blood or blood product. The first patent application describes a method for detecting active or past infection using Zika as an example. The second patent application describes a method for differentiating early from later stages of infection. According to the company, these technology breakthroughs could revolutionize point-of- care rapid assays for detection of acute infections including Zika. The Flaviviridae family has become a major concern in many areas of South America and more recently in the continental U.S.  As of early February 2016, the Brazil Ministry of Health has estimated that 500,000 to 1,500,000 cases of Zika virus disease have occurred since the beginning of the outbreak. The company says that with the high degree of cross-reactivity within the flaviviridae family, a diagnostic assay that can rapidly detect and differentiate between them, and determine new vs old infection, is of upmost importance. Story 6 Our final, and perhaps biggest story this week is a Canadian biotech business news story with Marlbourough, MA based-Sunovion Pharmaceuticals announcing that it is buying Toronto’s Cynapsus Therapeutics Inc. for approximately CDN$820 million. The transaction is the biggest the industry has seen in awhile for sure and has already received unanimous approval by the board of directors of both companies and The acquisition will be funded with cash on hand and is expected to close in the fourth quarter of 2016 (third quarter of Sunovion’s fiscal year). Pursuant to the terms of the agreement, and upon closing of the proposed transaction, shareholders of Cynapsus will receive US$40.50 per common share in cash, and holders of warrants and stock options will receive a cash payment equal to the difference between US$40.50 and the exercise price of such warrant or stock option. The offer of US$40.50 per common share in cash represents a premium of 123 per cent based on the volume weighted average closing price of Cynapsus’ common shares on the NASDAQ Global Market for the last twenty trading days. As part of the acquisition, Sunovion is getting Cynapsus’ lead product candidate, APL-130277, a sublingual thin film formulation of apomorphine designed to be an easy-to- use on-demand treatment option for managing OFF episodes associated with Parkinson’s disease (PD), a chronic, progressive neurodegenerative disease that affects more than four million worldwide. One of the biggest benefits of the sublingual thin film delivery of apomorphine is that avoids the normal gastrointestinal route of delivery used by most PD medications. Prior to the deal, Cynapsus had just announced that the Phase 3 clinical program for APL-130277 was nearing completion and that the company had plans to submit a new drug application (NDA) to the FDA in the first half of 2017.Nobuhiko Tamura, chairman and CEO, Sunovion said that his company sees APL-130277 as a novel late-stage candidate with the potential to make a real difference for patients and their families. He adds that Sunovian has high regard for the Cynapsus team led by Anthony Giovinazzo, president and CEO of Cynapsus and the work they have done with the APL-130277 program. For Cynapsus, the deal culminates years of dedicated work, and Anthony J. Giovinazzo, president and CEO, Cynapsus believes Sunovian is the ideal company to take APL-130277 forward. values Cynapsus at approximately CDN$820 million. The transaction will be completed by way of a plan of arrangement under the Canada Business Corporations Act. The arrangement will require approval of at least two-thirds of the votes cast by Cynapsus shareholders and warrantholders voting together as a single class at a special meeting of such securityholders of Cynapsus. This meeting will be held in October. With that we’ve come to the end of this week’s program. We hope you enjoyed it. A big thanks to our production manager Laskey Hart and the rest of the Biotechnology Focus team. You can find past episodes online at www.biotechnologyfocus.ca and we’re always looking for your feedback, story ideas and suggestions so we’d love to hear from you. Simply reach out to us on twitter: @BiotechFocus or by email biotechnology_focus@promotive.net.

Today in FirstWord:

1) Skin nerve a-synuclein deposits being a biomarker for idiopathic Parkinson disease and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Ratliff interviews Dr. Vincenzo Donadio about his paper on skin nerve ?-synuclein deposits being a biomarker for idiopathic Parkinson disease. Dr. Adam Numis is reading our e-Pearl of the week about cognitive impairment in pediatric multiple sclerosis. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Nathan Fountain about epilepsy therapeutics: Lacosamide. The participants had nothing to disclose except Drs. Fountain and Numis.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.

1) Rolandic epilepsy has little effect on adult life 30 years later and 2) Topic of the month: Therapeutics in epilepsy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Nathan Fountain interviews Drs. Carol and Peter Camfield about their paper on how rolandic epilepsy had little effect on adult life 30 years later. Dr. Adam Numis is reading our e-Pearl of the week about lower cranial nerve dysfunction. In the next part of the podcast Dr. Lara Marcuse interviews Dr. Jacqueline French about epilepsy therapeutics: Perampanel. There is different intro music, "Goofy Vocal Groove" by Dave Girtsman in this podcast. The song may be found at http://freemusicarchive.org/music/Dave_Girtsman/Silly_Songs/11_-_dave_girtsman_-_goofy_vocal_groove_kzz01_vbr. The original work was not changed ii any way and is licensed under a Attribution-NonCommercial-ShareAlike 3.0 International License. The participants had nothing to disclose except Drs. Fountain, Peter Camfield, Numis and French.Dr. Fountain serves as Vice-President of the National Association of Epilepsy Centers; performs EEG lab work and EEG interpretation in his clinical practice (10% effort); receives research support from UCB, SK Life Sciences, Sunovion, Medtronic, NeuroPace; and the NIH.Dr. Peter Camfield serves as an editorial board member of Journal of Child Neurology and Pediatric Neurology Epileptic Disorders Journal.Dr. Numis serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. French serves as an Associate Editor for Epilepsia; serves as an editorial board member of Lancet Neurology, Neurology Today, Epilepsy Currents; serves on the scientific advisory board for Electrocore, Epilepsy Therapy Project, UCB, Eisai Inc., SK Corporation, Marinus, Upsher-Smith Laboratories, Inc., Sunovion Inc., Vertex Pharmaceuticals, Novartis, Epilepsy Study Consortium; received paid travel to present findings at scientific meetings, present at investigators meetings attend advisory boards or give lectures from Acorda, UCB, Eisai, Inc., Johnson and Johnson, Upsher-Smith Laboratories, Inc., Novartis, Pfizer Inc, Eli Lilly and Company, LCGH, Vertex Pharmaceuticals, Supernus, Marinus Pharmaceuticals, Inc., SK Corporation; receives research support from Eisai, Inc., UCB, SK Corporation, Valeant Pharmaceuticals International, Upsher-Smith Laboratories, Inc., Vertex Pharmaceuticals, Pfizer Inc, Marinus Pharmaceuticals, Brain Sentinal, Epilepsy Research Foundation, The Milken Foundation, The Epilepsy Study Consortium and the NIH.